Provectus Biopharmaceuticals, Inc.
PVCT
$0.0923
-$0.0046-4.75%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -2.40M | -1.01M | -846.80K | -504.00K | -663.40K |
| Total Depreciation and Amortization | 500.00 | 2.20K | 2.20K | 2.20K | 2.20K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.29M | 11.90K | 11.80K | 11.60K | 11.50K |
| Change in Net Operating Assets | 191.60K | 435.20K | 70.30K | -554.30K | 88.50K |
| Cash from Operations | -912.00K | -565.00K | -762.60K | -1.04M | -561.20K |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 850.00K | 665.00K | 670.00K | 968.00K | 250.00K |
| Total Debt Repaid | -61.60K | -75.60K | -81.00K | -186.90K | -48.40K |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 788.40K | 589.40K | 589.00K | 781.10K | 201.60K |
| Foreign Exchange rate Adjustments | -900.00 | 500.00 | 200.00 | -600.00 | -23.70K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -124.50K | 24.90K | -173.50K | -264.00K | -383.40K |